The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials-Reference-Cited by-同舟云学术

The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials

Published:2024-07-10 Issue: Volume: Page:
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Kato Eri Toda¹²^ORCID,Hasegawa Koji³^ORCID,Ono Koh¹^ORCID

Affiliation:

1. Department of Cardiovascular Medicine, Kyoto University Hospital , 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507 , Japan

2. Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital , 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507 , Japan

3. Division of Translational Research, National Hospital Organization Kyoto Medical Centre , Kyoto 612-8555 , Japan

Funder

Ono Pharmaceutical

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvae053/58717605/pvae053.pdf

Reference5 articles.

1. Empagliflozin after acute myocardial infarction;Butler;N Engl J Med,2024

2. Dapagliflozin in myocardial infarction without diabetes or heart failure;James;NEJM Evid,2024

3. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting;Kato;EHJ CVP,2024

4. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators;Pfeffer;N Engl J Med,1992

5. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both;Pfeffer;N Engl J Med,2003